Why do some cancer patients experience remarkable improvements with immunotherapy while others receive little or no benefit? Although immunotherapy has transformed the management of several malignancies, treatment responses remain highly variable.
Unlike conventional chemotherapy, which primarily targets rapidly dividing cells, many immunotherapies stimulate or modify the immune system’s ability to recognise and destroy malignant cells. However, cancer cells possess complex biological mechanisms that allow them to evade immune surveillance.
The effectiveness of immunotherapy depends on tumour characteristics, molecular biomarkers, immune system activity and individual medical circumstances. Understanding these factors can help patients appreciate why oncologists recommend different treatments for apparently similar cancers.
How Does Cancer Immunotherapy Work?
Cancer immunotherapy is a therapeutic approach that strengthens, modifies or redirects the immune system’s ability to recognise and eliminate malignant cells. Unlike conventional chemotherapy, which primarily targets rapidly dividing cells, many immunotherapies work by improving immune recognition or overcoming mechanisms that prevent effective antitumour responses.
Under normal physiological conditions, the immune system continuously monitors tissues for abnormal cellular activity. Specialised immune cells, particularly cytotoxic T lymphocytes, can identify and destroy cells displaying suspicious molecular characteristics. However, malignant cells frequently develop sophisticated mechanisms that allow them to escape immune surveillance, suppress immune responses or interfere with normal immune signalling.
Immune checkpoint inhibitors represent one of the most widely used forms of cancer immunotherapy. These medications target regulatory pathways involving programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). By blocking inhibitory signals, checkpoint inhibitors can restore or strengthen the ability of T cells to attack cancerous tissue.
Another approach is chimeric antigen receptor (CAR) T-cell therapy, which involves modifying a patient’s T cells in a laboratory to recognise specific proteins expressed by malignant cells. This treatment has demonstrated considerable effectiveness in selected haematological malignancies, including certain leukaemias, lymphomas and multiple myeloma.
Additional immunotherapeutic strategies include therapeutic cancer vaccines, bispecific antibodies and other monoclonal antibody-based treatments. Each approach targets different aspects of tumour biology and immune system regulation.
Nevertheless, successful treatment depends on several biological conditions. Cancer cells must possess recognisable targets, immune cells must function adequately, and the surrounding tumour environment must permit an effective immune response.
Consequently, although immunotherapy has expanded cancer treatment possibilities, its effectiveness varies substantially between malignancies and individual patients.
1. Cancer Type, Stage and Biological Characteristics
The type of cancer is one of the most important factors influencing immunotherapy effectiveness. Certain malignancies, including melanoma, non-small-cell lung cancer and some renal cancers, have demonstrated substantial benefits from specific immune checkpoint inhibitors. However, other tumours respond less consistently to these treatments.
Disease stage and tumour burden can also influence treatment planning. Extensive malignancy may create additional challenges for effective immune-mediated tumour elimination, although advanced-stage cancer can still respond favourably.
Oncologists evaluate histological classification, disease distribution, previous treatments, and available clinical evidence before recommending an immunotherapeutic regimen.
Importantly, a particular cancer diagnosis does not guarantee either treatment success or failure.
2. Tumour Biomarkers and Genetic Alterations
Molecular characteristics can help oncologists determine whether a patient is likely to benefit from particular immunotherapies.
One commonly evaluated biomarker is programmed death-ligand 1 (PD-L1), a protein that can suppress T-cell activity by interacting with the PD-1 receptor.
In certain cancers, increased PD-L1 expression may indicate a greater likelihood of responding to checkpoint inhibition. However, some patients with low PD-L1 expression also benefit.
Other relevant biomarkers include microsatellite instability-high (MSI-H), deficient mismatch repair (dMMR) and tumour mutational burden (TMB). Patients considering immunotherapy in abu dhabi should discuss whether molecular profiling is appropriate for their cancer diagnosis. Biomarker testing informs treatment selection but cannot predict outcomes with absolute certainty.
3. The Tumour Microenvironment and Immune Cell Activity
The tumour microenvironment consists of malignant cells, immune cells, blood vessels, connective tissue and signalling molecules surrounding the cancer. This environment plays a substantial role in determining whether immunotherapy can produce an effective antitumour response.
Some tumours contain considerable numbers of tumour-infiltrating lymphocytes, particularly cytotoxic T cells capable of recognising malignant cells. Others exhibit limited immune cell infiltration or contain immunosuppressive populations, including regulatory T cells and certain myeloid-derived suppressor cells.
Furthermore, inadequate blood supply, abnormal tissue architecture, and immunosuppressive cytokines may interfere with immune cell function. Researchers are investigating combination therapies that modify the tumour microenvironment to improve treatment responsiveness. However, these approaches remain dependent on cancer type and supporting clinical evidence.
4. Cancer’s Ability to Develop Treatment Resistance
Even when immunotherapy initially produces tumour regression, its effectiveness may diminish over time. This phenomenon is known as acquired resistance. Conversely, primary resistance occurs when a malignancy fails to respond meaningfully from the beginning. Cancer cells can evade immune destruction through several molecular mechanisms.
Some develop alterations affecting antigen presentation, preventing immune cells from recognising malignant targets. Others acquire abnormalities in interferon signalling pathways or activate alternative immunosuppressive mechanisms. Tumour heterogeneity adds further complexity because different malignant cell populations within the same tumour may respond differently to treatment.
Consequently, immunotherapy may eliminate susceptible cancer cells while resistant populations continue proliferating. Oncologists monitor treatment effectiveness using clinical examinations, diagnostic imaging and appropriate laboratory investigations. When progression occurs, alternative systemic treatments or suitable clinical trials may be considered.
5. Patient Health, Immune Function and Treatment Tolerance
Individual medical circumstances also influence whether immunotherapy is appropriate and can be administered safely. Patients with pre-existing autoimmune disorders, organ transplants or conditions requiring immunosuppressive medication may face additional treatment challenges. Immune checkpoint inhibitors can provoke immune-related adverse events, including pneumonitis, colitis, hepatitis, and endocrine dysfunction.
Severe toxicity may require temporary treatment interruption, corticosteroid administration, or permanent discontinuation. Physicians also consider performance status, organ function, concurrent medications, and previous anticancer therapies when assessing treatment suitability.
Medical complexity does not automatically exclude every patient from immunotherapy. Instead, oncologists assess the anticipated therapeutic benefit against individual risks. Multidisciplinary cancer services, including those available at cleveland clinic abu dhabi, support coordinated assessment and individualised treatment planning.
What Happens When Immunotherapy Does Not Work?
An inadequate response does not necessarily mean that all available cancer treatments have been exhausted. Oncologists may reassess the diagnosis, review molecular findings and evaluate disease progression before recommending another therapeutic approach.
Depending on the malignancy, alternatives may include chemotherapy, targeted therapy, radiotherapy, or another evidence-supported systemic treatment.
Some patients may qualify for clinical trials investigating new immunotherapeutic combinations or approaches to overcoming resistance. Treatment decisions should also consider symptom control, quality of life, and the patient’s preferences.
Questions to Discuss With Your Oncologist
Before starting immunotherapy, ask which clinical findings support its use, whether biomarker testing is required, and how treatment effectiveness will be assessed.
Patients should also understand possible immune-related complications, the anticipated treatment schedule, and available alternatives if the malignancy does not respond.
Conclusion
Immunotherapy offers substantial therapeutic benefits for selected cancer patients, but its effectiveness depends on complex interactions between malignant cells and the immune system.
Cancer biology, molecular biomarkers, the tumour microenvironment, resistance mechanisms, and individual health characteristics all contribute to treatment outcomes. No single factor can reliably determine success. Comprehensive diagnostic evaluation and personalised oncology assessment remain essential for identifying appropriate candidates and selecting the most suitable treatment strategy.

